FINWIRES · TerminalLIVE
FINWIRES

Atlas Arteria's Target Statement on Acquisition Proposal Risks Misleading Shareholders, IFM Global Says

By

Atlas Arteria's (ASX:ALX) target's statement related to IFM Global Infrastructure Fund's proposal to acquire the company contains a number of omissions and "unreasonable assumptions" that risk misleading shareholders, IFM said in a Monday filing with the Australian bourse.

IFM Global unit Diamond Infraco 1 has proposed to acquire Atlas Arteria at AU$4.75 per share in cash, with the consideration potentially increasing to AU$5.10 per share if IFM obtains at least a 45% relevant interest before the offer closes.

An independent expert's report commissioned by Atlas treats the recently rejected right-of-first-offer price for Chicago Skyway toll road in the US as a market-based valuation, but should instead have included a risk-weighted valuation of Atlas' liability under the Ontario Teachers' Pension Plan put option, IFM Global argued.

IFM said its proposed maximum consideration of AU$5.10 per security, if achieved, would deliver "full value for Chicago Skyway."

The independent directors' belief that further value can be created via asset disposals or operational initiatives "is not credible," and Atlas' proposed use of a $1.2 billion bridge facility will raise financial risk, IFM said.

Atlas Arteria did not immediately respond to a request for comment from.

The company's shares gained nearly 2% in recent Monday trade.

Related Articles

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783